Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised double-blind phase II trial of Tocovid SupraBio plus pentoxifylline for chronic gastrointestinal adverse effects after pelvic radiotherapy
2012-004211-31Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jun 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tocovid and pentoxifylline in Radiation-induced gastrointestinal syndrome (RIGS), Radiation-Induced Injury and pelvic malignancies (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Change at 12 months in the bowel disease subset of the Modified IBDQ Quality of Life questionnaire. Started Jun 2014; status: completed.
02
Drugs
tocovidpentoxifylline
03
Conditions
Radiation-induced gastrointestinal syndrome (RIGS)Radiation-Induced Injurypelvic malignancies
Beyond the preview
Go deeper on 2012-004211-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004211-31.